Severe eosinophilic asthma patients in South Korea may soon see lower out-of-pocket treatment costs: on Monday afternoon, the Korean Academy of Asthma, Allergy and Clinical Immunology convened a policy forum at the National Assembly Members’ Office Building to push for expanded insurance coverage, MEDI:GATE NEWS reported.
The forum, held at 3 p.m. in meeting room 11 of the assembly building, was co-hosted by Rep. Seo Young-seok and Rep. Kim Yun of the National Assembly’s Health and Welfare Committee, and organized jointly by the academy and the Korean Severe Eosinophilic Asthma Patient Association.
Its stated aim: to examine the treatment blind spots facing patients who suffer repeated acute exacerbations and hospitalizations, and to debate strengthening coverage — including designation of the disease under Korea’s “special case calculation for rare and intractable diseases,” which sharply reduces patient copayments.
The academy told MEDI:GATE NEWS that patients who need specialized diagnosis and treatment concentrated at large tertiary hospitals are experiencing high outpatient copays and overall treatment costs that put care out of reach.
What makes the forum consequential is the specific mechanism under discussion. Special case designation would lower the patient’s share of the bill.
Severe Eosinophilic Asthma Inflames Airways, Triggers Attacks
- Severe eosinophilic asthma is driven by high levels of eosinophils, immune cells that inflame the airways and trigger repeated attacks.
- The forum’s concrete ask is a government “designation evaluation” that would place the disease under the special copay program — lowering what patients pay per dose.
Where Care Gaps Show Up in the Clinic
He reviewed the financial impact on medical spending tied to the new disease code J82.12 — created in 2026 — and the institutional blind spots around it, then laid out policy directions for easing patients' actual financial burden.
“In clinical practice, we not infrequently encounter patients for whom treatment effect is expected, but who hesitate to start or continue treatment because of the cost burden,” said Professor Kim Joo-hee of Hallym University Sacred Heart Hospital.
“Because how well acute exacerbations are prevented determines the prognosis in severe eosinophilic asthma, institutional supplements such as special case designation must be made quickly so patients do not give up treatment for economic reasons.”
That framing matters clinically: in eosinophilic asthma, the damage is cumulative. Each exacerbation — an acute worsening requiring oral steroids, emergency care or admission — compounds airway remodeling. Preventing flares is not a comfort measure; it is the prognostic lever.
A Caregiver’s Account, and the Insurer’s Seat at the Table
Vice Chairperson Cho Kyung-sook of the patient association appealed directly to the National Assembly and the government to act.
Hong Ji-sun, the parent of a child battling the disease, drew the sharpest line of the afternoon.
“That a treatment exists and that a patient can actually receive it are entirely different stories,” Hong said. “What patients want is not a vague promise, but knowing what is actually being done after the words ‘we will review it.'”
The presence of both the National Health Insurance Service and the Ministry of Health and Welfare on the panel is itself notable. Coverage decisions in Korea’s single-payer system turn on such evaluations, and the forum was structured to put the payer’s fiscal concerns in the same room as patient testimony.
The Fiscal Argument for Coverage
Academy President Lim Dae-hyun closed the discussion by making the payer’s own case for the change, MEDI:GATE NEWS reported.
“Even if special case designation lowers the patient copayment rate, the costs of hospitalization and emergency care from acute exacerbations and the treatment costs of complications will fall, which can raise the long-term efficiency of health insurance finances,” said Lim Dae-hyun, president of the academy. “Through a prompt designation evaluation and application, the treatment environment for patients must be improved.”
That argument mirrors the access debates playing out in other health systems. Korea’s special case designation is its own analogue — a coverage tier that determines whether a costly therapy is financially survivable for the patient.
| Forum element | Detail |
|---|---|
| Event | Policy forum on strengthening treatment access for severe eosinophilic asthma |
| Date and venue | Monday, 3 p.m., meeting room 11, National Assembly Members’ Office Building |
| Co-hosts | Rep. Seo Young-seok, Rep. Kim Yun (Health and Welfare Committee) |
| Organizers | Korean Academy of Asthma, Allergy and Clinical Immunology; Korean Severe Eosinophilic Asthma Patient Association |
| Core proposal | Special case designation for rare/intractable diseases to lower patient copayments |
| New administrative marker | Disease code J82.12, newly created in 2026 |
Treatment Requires Confirmed Eosinophilic Inflammation, Specialist Prescription
It is generally reserved for those with confirmed eosinophilic inflammation — documented by blood eosinophil counts and recurrent exacerbations despite high-dose inhaled corticosteroid therapy — and prescribing decisions rest with a pulmonologist or allergist, not with patient demand alone.
The concrete next step the forum produced is procedural, not ceremonial: advocacy for a prompt government designation evaluation that would test whether severe eosinophilic asthma qualifies for the special copay program. Hong Ji-sun's measure of the process stands as the benchmark patients will apply:
References
- MEDI:GATE NEWS, report on the Korean Academy of Asthma, Allergy and Clinical Immunology policy forum on treatment access for severe eosinophilic asthma (November 18, 2026 session).
- Korean Academy of Asthma, Allergy and Clinical Immunology — forum proceedings and speaker presentations as reported.
- Korean Severe Eosinophilic Asthma Patient Association — patient testimony presented at the forum.
Disclaimer: This article is news reporting and does not constitute medical advice. Treatment decisions for severe eosinophilic asthma should be made with a qualified pulmonologist or allergist.
Keep reading
- How AI Could Reimagine or Replace Primary Care: Oura’s $625M Bet on Counsel Health
- New UK AD-SMART Trial Tests Repurposed Drugs to Accelerate Alzheimer’s Treatment Search
- South Korea Supports Possible Trump-Kim Summit as APEC Speculation Grows (world-today-news.com)
- After A.I. Cheating Scandal, South Korea Adopts New Restrictions for Grueling College Entrance Exam (time.news)